DEGS1 and prostate cancer: We have previously show that the treatment of LNCaP prostate cancer cells with SKi results in a substantial increase in the levels of several different molecular species of dihydroceramide [4] suggesting, in agreement with Cingolani et al. [19], that SKi inhibits Des1 activity.